FDA clarifies its rules on CMO interruptions; Almac buys new equipment; ERT enjoys revenue growth;

> Anxious to steer clear of future drug shortages, the FDA is warning sole-source suppliers of drugs that they still have to notify the agency of any manufacturing interruptions, even if they've outsourced the manufacturing process to a CMO. The agency has been grappling with a public relations nightmare as patients and physicians complain of a growing problem finding needed meds, including some crucial cancer drugs. Report

> Almac has acquired two new pieces of encapsulation equipment. Release

> ERT's new CEO says the decision to stop turning away business has helped push revenue growth. Story

> Charles River Laboratories is licensing EMD Millipore's TrueSpike technology to clean up virus preparations used to validate biomanufacturing process virus clearance. Release


Suggested Articles

California clinical trial artificial intelligence startup Saama Technologies has teamed up with Big Pharma Pfizer.

Contract research organization Worldwide Clinical Trials has hired Mike Mencer as EVP and general manager of its early-phase services.

Getting the right patients into the right trial at the right time, and keeping them there, is a tough gig.